Cargando…

TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases

Papillary thyroid carcinoma (PTC) is the most common type of endocrine malignancy and accounts for ~80% of thyroid carcinomas in adults and 90% in children. Risk stratification is important for identifying patients at higher risk and, for this reason, recent advances in molecular genetics of thyroid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Insilla, Andrea Cacciato, Proietti, Agnese, Borrelli, Nicla, Macerola, Elisabetta, Niccoli, Cristina, Vitti, Paolo, Miccoli, Paolo, Basolo, Fulvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778878/ https://www.ncbi.nlm.nih.gov/pubmed/29435002 http://dx.doi.org/10.3892/ol.2017.7675

Ejemplares similares

Down-regulation of miR-7-5p and miR-548ar-5p predicts malignancy in indeterminate thyroid nodules negative for BRAF and RAS mutations
por: Macerola, Elisabetta, et al.
Publicado: (2022)

Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report
por: Pani, Fabiana, et al.
Publicado: (2017)

Metastasis of renal cell carcinoma to the parathyroid gland 16 years after radical nephrectomy: A case report
por: Torregrossa, Liborio, et al.
Publicado: (2016)

A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
por: Poma, Anello Marcello, et al.
Publicado: (2017)

Predictive Biomarkers in Thyroid Cancer
por: Macerola, Elisabetta, et al.
Publicado: (2022)

Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma
por: Macerola, Elisabetta, et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions
por: Poma, Anello Marcello, et al.
Publicado: (2019)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution
por: Macerola, Elisabetta, et al.
Publicado: (2021)

MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions
por: Macerola, E., et al.
Publicado: (2023)

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry
por: Estrada-Flórez, Ana P, et al.
Publicado: (2019)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center
por: Vignali, Paola, et al.
Publicado: (2022)

Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional Experience
por: Proietti, Agnese, et al.
Publicado: (2023)

Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit
por: Censi, Simona, et al.
Publicado: (2017)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules
por: Fallahi, Poupak, et al.
Publicado: (2014)

The 5(th) edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma
por: Basolo, Fulvio, et al.
Publicado: (2023)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
por: Jin, Langping, et al.
Publicado: (2016)

Utility of droplet digital polymerase chain reaction for TERT and BRAF mutational profiling of thyroid nodules
por: Rosvall, Brandon R., et al.
Publicado: (2021)

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation
por: Kikuchi, Yasuko, et al.
Publicado: (2013)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
por: Shetty, Omshree, et al.
Publicado: (2022)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
por: Le Calvez, Baptiste, et al.
Publicado: (2020)

CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer
por: Cetani, Filomena, et al.
Publicado: (2013)

The italian consensus for the classification and reporting of thyroid cytology: Cytohistologic and molecular correlations on 37,371 nodules from a single institution
por: Torregrossa, Liborio, et al.
Publicado: (2022)

BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
por: Oikonomou, Eftychia, et al.
Publicado: (2014)

RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAF(V600E) Mutation-Negative Nodules?
por: Yoon, Jung Hyun, et al.
Publicado: (2015)

Indeterminate Thyroid Nodules: From Cytology to Molecular Testing
por: Vignali, Paola, et al.
Publicado: (2023)

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
por: Miller, Mark Steven, et al.
Publicado: (2012)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas
por: Ylli, Dorina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7vum0l5fabtnv3ba94vrqv3cal